Stocks
Merck & Co. Stock Down 0.01 Percent Following FDA Approval
Merck & Co.'s stock price closed at $147.97 in New York trading on September 25, 2026, marking a decline of 0.01 percent from its previous session level.
The FDA approved Welireg plus Lenvima for certain previously treated renal-cell carcinoma patients earlier that day, which could have contributed to the company's stock movement.
Merck traded 0.54 percentage points below the Nasdaq Composite, which was up 0.53 percent at 12:39 p.m. ET.
The company's European Tradegate quotation was EUR 129.64, down 0.34 percent at 10:47 a.m. CET on September 25, 2026.